Investigating how mutant p53 affects metabolism in colorectal cancer
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer
This study is looking at how a changed version of a protein called p53 affects fat processing in colorectal cancer, with the hope of finding new treatment options for patients dealing with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11054564 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a mutated form of the p53 protein in colorectal cancer, particularly how it alters lipid metabolism to promote tumor growth. The study aims to identify the mechanisms by which this mutant p53 drives changes in cancer cell metabolism and to explore potential therapeutic strategies that target these metabolic changes. By using specific mouse models, researchers will assess the impact of targeting lipid metabolism on colorectal tumors that carry the mutant p53. This approach could lead to new treatment options for patients with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer that has mutations in the p53 gene.
Not a fit: Patients with colorectal cancer that do not have p53 mutations may not benefit from the findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target metabolic changes in colorectal cancer, improving treatment outcomes for patients with mutant p53.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach may be effective, although the specific focus on mutant p53 in colorectal cancer is relatively novel.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Hu, Wenwei — Rutgers Biomedical and Health Sciences
- Study coordinator: Hu, Wenwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.